Hif1α is required for osteoclast activation and bone loss in male osteoporosis

Toshimi Tando, Yuiko Sato, Kana Miyamoto, Mayu Morita, Tami Kobayashi, Atsushi Funayama, Arihiko Kanaji, Wu Hao, Ryuichi Watanabe, Takatsugu Oike, Masaya Nakamura, Morio Matsumoto, Yoshiaki Toyama, Takeshi Miyamoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The number of osteoporosis patients is increasing not only in women but in men. Male osteoporosis occurs due to aging or androgen depletion therapies, leading to fractures. However, molecular mechanisms underlying male osteoporosis remain unidentified. Here, we show that hypoxia inducible factor 1 alpha (Hif1α) is required for development of testosterone deficiency-induced male osteoporosis. We found that in mice Hif1α protein accumulates in osteoclasts following orchidectomy (ORX) in vivo. In vitro, Hif1α protein accumulated in osteoclasts cultured in hypoxic conditions, but Hif1α protein rather than mRNA levels were suppressed by testosterone treatment, even in hypoxia. Administration of a Hif1α inhibitor to ORX mice abrogated testosterone deficiency-induced osteoclast activation and bone loss but did not alter osteoclast activities or bone phenotypes in sham-operated, testosterone-sufficient animals. We conclude that Hif1α protein accumulation due to testosterone-deficiency promotes development of male osteoporosis. Thus Hif1α protein could be targeted to inhibit pathologically-activated osteoclasts under testosterone-deficient conditions to treat male osteoporosis patients.

Original languageEnglish
Pages (from-to)391-396
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume470
Issue number2
DOIs
Publication statusPublished - 2016 Feb 5
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor 1
Osteoclasts
Osteoporosis
Bone
Chemical activation
Testosterone
Bone and Bones
Proteins
Orchiectomy
Androgens
Animals
Aging of materials
Phenotype
Messenger RNA
Therapeutics

Keywords

  • Bone
  • Hif1α
  • Male
  • Osteoclasts
  • Osteoporosis
  • Testosterone

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Tando, T., Sato, Y., Miyamoto, K., Morita, M., Kobayashi, T., Funayama, A., ... Miyamoto, T. (2016). Hif1α is required for osteoclast activation and bone loss in male osteoporosis. Biochemical and Biophysical Research Communications, 470(2), 391-396. https://doi.org/10.1016/j.bbrc.2016.01.033

Hif1α is required for osteoclast activation and bone loss in male osteoporosis. / Tando, Toshimi; Sato, Yuiko; Miyamoto, Kana; Morita, Mayu; Kobayashi, Tami; Funayama, Atsushi; Kanaji, Arihiko; Hao, Wu; Watanabe, Ryuichi; Oike, Takatsugu; Nakamura, Masaya; Matsumoto, Morio; Toyama, Yoshiaki; Miyamoto, Takeshi.

In: Biochemical and Biophysical Research Communications, Vol. 470, No. 2, 05.02.2016, p. 391-396.

Research output: Contribution to journalArticle

Tando, T, Sato, Y, Miyamoto, K, Morita, M, Kobayashi, T, Funayama, A, Kanaji, A, Hao, W, Watanabe, R, Oike, T, Nakamura, M, Matsumoto, M, Toyama, Y & Miyamoto, T 2016, 'Hif1α is required for osteoclast activation and bone loss in male osteoporosis', Biochemical and Biophysical Research Communications, vol. 470, no. 2, pp. 391-396. https://doi.org/10.1016/j.bbrc.2016.01.033
Tando, Toshimi ; Sato, Yuiko ; Miyamoto, Kana ; Morita, Mayu ; Kobayashi, Tami ; Funayama, Atsushi ; Kanaji, Arihiko ; Hao, Wu ; Watanabe, Ryuichi ; Oike, Takatsugu ; Nakamura, Masaya ; Matsumoto, Morio ; Toyama, Yoshiaki ; Miyamoto, Takeshi. / Hif1α is required for osteoclast activation and bone loss in male osteoporosis. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 470, No. 2. pp. 391-396.
@article{dc3ff38004aa4dc2b24dd1acc88c6225,
title = "Hif1α is required for osteoclast activation and bone loss in male osteoporosis",
abstract = "The number of osteoporosis patients is increasing not only in women but in men. Male osteoporosis occurs due to aging or androgen depletion therapies, leading to fractures. However, molecular mechanisms underlying male osteoporosis remain unidentified. Here, we show that hypoxia inducible factor 1 alpha (Hif1α) is required for development of testosterone deficiency-induced male osteoporosis. We found that in mice Hif1α protein accumulates in osteoclasts following orchidectomy (ORX) in vivo. In vitro, Hif1α protein accumulated in osteoclasts cultured in hypoxic conditions, but Hif1α protein rather than mRNA levels were suppressed by testosterone treatment, even in hypoxia. Administration of a Hif1α inhibitor to ORX mice abrogated testosterone deficiency-induced osteoclast activation and bone loss but did not alter osteoclast activities or bone phenotypes in sham-operated, testosterone-sufficient animals. We conclude that Hif1α protein accumulation due to testosterone-deficiency promotes development of male osteoporosis. Thus Hif1α protein could be targeted to inhibit pathologically-activated osteoclasts under testosterone-deficient conditions to treat male osteoporosis patients.",
keywords = "Bone, Hif1α, Male, Osteoclasts, Osteoporosis, Testosterone",
author = "Toshimi Tando and Yuiko Sato and Kana Miyamoto and Mayu Morita and Tami Kobayashi and Atsushi Funayama and Arihiko Kanaji and Wu Hao and Ryuichi Watanabe and Takatsugu Oike and Masaya Nakamura and Morio Matsumoto and Yoshiaki Toyama and Takeshi Miyamoto",
year = "2016",
month = "2",
day = "5",
doi = "10.1016/j.bbrc.2016.01.033",
language = "English",
volume = "470",
pages = "391--396",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Hif1α is required for osteoclast activation and bone loss in male osteoporosis

AU - Tando, Toshimi

AU - Sato, Yuiko

AU - Miyamoto, Kana

AU - Morita, Mayu

AU - Kobayashi, Tami

AU - Funayama, Atsushi

AU - Kanaji, Arihiko

AU - Hao, Wu

AU - Watanabe, Ryuichi

AU - Oike, Takatsugu

AU - Nakamura, Masaya

AU - Matsumoto, Morio

AU - Toyama, Yoshiaki

AU - Miyamoto, Takeshi

PY - 2016/2/5

Y1 - 2016/2/5

N2 - The number of osteoporosis patients is increasing not only in women but in men. Male osteoporosis occurs due to aging or androgen depletion therapies, leading to fractures. However, molecular mechanisms underlying male osteoporosis remain unidentified. Here, we show that hypoxia inducible factor 1 alpha (Hif1α) is required for development of testosterone deficiency-induced male osteoporosis. We found that in mice Hif1α protein accumulates in osteoclasts following orchidectomy (ORX) in vivo. In vitro, Hif1α protein accumulated in osteoclasts cultured in hypoxic conditions, but Hif1α protein rather than mRNA levels were suppressed by testosterone treatment, even in hypoxia. Administration of a Hif1α inhibitor to ORX mice abrogated testosterone deficiency-induced osteoclast activation and bone loss but did not alter osteoclast activities or bone phenotypes in sham-operated, testosterone-sufficient animals. We conclude that Hif1α protein accumulation due to testosterone-deficiency promotes development of male osteoporosis. Thus Hif1α protein could be targeted to inhibit pathologically-activated osteoclasts under testosterone-deficient conditions to treat male osteoporosis patients.

AB - The number of osteoporosis patients is increasing not only in women but in men. Male osteoporosis occurs due to aging or androgen depletion therapies, leading to fractures. However, molecular mechanisms underlying male osteoporosis remain unidentified. Here, we show that hypoxia inducible factor 1 alpha (Hif1α) is required for development of testosterone deficiency-induced male osteoporosis. We found that in mice Hif1α protein accumulates in osteoclasts following orchidectomy (ORX) in vivo. In vitro, Hif1α protein accumulated in osteoclasts cultured in hypoxic conditions, but Hif1α protein rather than mRNA levels were suppressed by testosterone treatment, even in hypoxia. Administration of a Hif1α inhibitor to ORX mice abrogated testosterone deficiency-induced osteoclast activation and bone loss but did not alter osteoclast activities or bone phenotypes in sham-operated, testosterone-sufficient animals. We conclude that Hif1α protein accumulation due to testosterone-deficiency promotes development of male osteoporosis. Thus Hif1α protein could be targeted to inhibit pathologically-activated osteoclasts under testosterone-deficient conditions to treat male osteoporosis patients.

KW - Bone

KW - Hif1α

KW - Male

KW - Osteoclasts

KW - Osteoporosis

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=84956595462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956595462&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.01.033

DO - 10.1016/j.bbrc.2016.01.033

M3 - Article

C2 - 26792721

AN - SCOPUS:84956595462

VL - 470

SP - 391

EP - 396

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -